Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Patient

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40271-014-0075-yPMID 25015302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis

  2014cited by this paper
• Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.

  2014cited by this paper
• Evaluation of Patient Preference and Willingness to Pay for Attributes of Maintenance Medication for Chronic Obstructive Pulmonary Disease (COPD)

  2014cited by this paper
• Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis

  2014cited by this paper
• Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors.

  2014cited by this paper
• Subcutaneous Versus Intravenous Bortezomib

  2013cited by this paper
• Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

  2013cited by this paper
• Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

  2013influential reference
• Subcutaneous versus intravenous insulin therapy for glucose control in non‐diabetic trauma patients. A randomized controlled trial

  2013cited by this paper
• Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

  2013cited by this paper
• Why I Use Subcutaneous Immunoglobulin (SCIG)

  2012cited by this paper
• Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

  2012cited by this paper
• Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

  2012cited by this paper
• Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis

  2012cited by this paper
• Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

  2011influential reference
• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

  2011cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011influential reference
• Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study).

  2010cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• How do patients with inflammatory bowel disease want their biological therapy administered?

  2010cited by this paper
• A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.

  2010cited by this paper
• A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously.

  2009cited by this paper
• Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trial

  2009influential reference
• Rapid vascular glucose uptake via enzyme-assisted subcutaneous infusion: enzyme-assisted subcutaneous infusion access study.

  2009cited by this paper
• Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis?

  2009cited by this paper
• Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.

  2007cited by this paper
• Patient preferences in choosing anti-TNF therapies-R1.

  2006cited by this paper
• Patient preferences in choosing anti-TNF therapies

  2006cited by this paper
• Intravenous versus Subcutaneous Morphine Titration in Patients with Persisting Exacerbation of Cancer Pain

  2005cited by this paper
• Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

  2005cited by this paper
• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  2003cited by this paper
• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  2003cited by this paper
• Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.

  2002cited by this paper
• 529 The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy

  2000cited by this paper
• The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy

  2000cited by this paper
• Understanding controlled trials: Why are randomised controlled trials important?

  1998cited by this paper
• A comparison of intravenous and subcutaneous hydration in elderly acute stroke patients.

  1994cited by this paper
• Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over study.

  1992influential reference
• A new measure of health status for clinical trials in inflammatory bowel disease.

  1989influential reference
• Patient-controlled analgesia: a comparison of intravenous versus subcutaneous hydromorphone.

  1988influential reference

• Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study.

  2026cites this paper
• High concentration subcutaneous biological drug products: challenges and advancements.

  2026cites this paper
• The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

  2026cites this paper
• Transdermal Needle-Free Drug Delivery Approaches and Activation Mechanism

  2026cites this paper
• Advancing Patient Care with the GRAVITI Trial.

  2025cites this paper
• Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment.

  2025cites this paper
• Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

  2025cites this paper
• When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study.

  2025cites this paper
• Multiscale Diffusion, Dynamic Cluster Formation, and Intermolecular Interactions in Pharmaceutically Relevant Monoclonal Antibody Formulations.

  2025cites this paper
• Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria

  2025cites this paper
• Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone in an Older Population: The PhASAge Study

  2025cites this paper
• A detailed review of the recent development of needle-free drug delivery devices

  2025cites this paper
• PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission.

  2025cites this paper
• Pharmacokinetics of Psilocybin: A Systematic Review

  2025cites this paper
• Comparative Efficacy of Subcutaneous Compared to Intravenous Biologics for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

  2025cites this paper
• Comparative Efficacy of Subcutaneous Versus Intravenous Interleukin 12/23 Inhibitors for the Remission of Moderate to Severe Crohn’s Disease: A Systematic Review and Meta-Analysis

  2025cites this paper
• An industry perspective on hyaluronidase co-formulated biopharmaceutics.

  2025cites this paper
• Patient segmentation and resource allocation for tailored healthcare delivery

  2025cites this paper
• Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients-the PhASAge Study.

  2025cites this paper
• Expert opinion on hot topics in the field of IBD.

  2025cites this paper
• Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach

  2025cites this paper
• Systematic Literature Review of Outcomes Associated With Adherence to Haemophilia Drug Therapy

  2025cites this paper
• Injection site reactions of biologics and mitigation strategies

  2025cites this paper
• The Needle Shield Size and Applied Force of Subcutaneous Autoinjectors Significantly Influence the Injection Depth

  2024cites this paper
• SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis

  2024cites this paper
• Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected.

  2024cites this paper
• Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies

  2024cites this paper
• Preventing osteoporotic bone loss in mice by promoting balanced bone remodeling through M-CSFRGD, a dual antagonist to c-FMS and αvβ3 receptors.

  2024cites this paper
• Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management

  2024cites this paper
• Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study

  2024cites this paper
• Enhancing systemic anti-cancer treatment (SACT) capacity: implementing and using subcutaneous atezolizumab.

  2024cites this paper
• Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products

  2024cites this paper
• Drug Product Development and Case Studies for User Centric Pediatric Protein-Based Therapeutics.

  2024cites this paper
• Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial

  2024cites this paper
• Glucans: A Therapeutic Alternative for Sepsis Treatment

  2024cites this paper
• Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design.

  2024cites this paper
• Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

  2024cites this paper
• Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

  2024cites this paper
• Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

  2024cites this paper
• Patient experience of medication administration and development of a Patient Experience and Preference Questionnaire (PEPQ) for patients with advanced or metastatic cancer

  2024cites this paper
• Subcutaneous drug delivery from nanoscale systems

  2024cites this paper
• Rheological and Lipid Characterization of Minipig and Human Skin Tissue: A Comparative Study Across Different Locations and Depths

  2024cites this paper
• Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial.

  2024cites this paper
• Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

  2024cites this paper
• Assessing physiochemical stability of monoclonal antibodies in a simulated subcutaneous environment.

  2024cites this paper
• Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

  2024cites this paper
• Microscopic Cascading Devices for Boosting Mucus Penetration in Oral Drug Delivery-Micromotors Nesting Inside Microcontainers.

  2023cites this paper
• Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring

  2023cites this paper
• Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

  2023cites this paper
• Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants

  2023cites this paper
• Imaging of large volume subcutaneous deposition using MRI: exploratory clinical study results

  2023cites this paper
• Acceptability of intramuscular injection of tranexamic acid in postpartum hemorrhage prevention

  2023cites this paper
• Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

  2023cites this paper
• A review of paediatric injectable drug delivery to inform the study of product acceptability - an introduction.

  2023cites this paper
• A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations

  2023cites this paper
• One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.

  2023cites this paper
• Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions

  2023cites this paper
• International Consensus Recommendation Guidelines for Subcutaneous Infusions of Hydration and Medication in Adults

  2023cites this paper
• Concentration‐dependent diffusion of unlabeled protein within an in vitro hyaluronic acid matrix

  2023cites this paper
• Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.

  2023cites this paper
• Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies

  2023cites this paper
• Delivery of biologics: Topical administration.

  2023cites this paper
• Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis

  2023cites this paper
• Comparing Patient Preference Between At-home and In-hospital Settings: Systematic Review and Meta-Analysis on Injectable Medications

  2023cites this paper
• Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment

  2023cites this paper
• Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review

  2023cites this paper
• Subcutaneous versus intravenous tramadol for extremity injury with moderate pain in the emergency department: a randomised controlled noninferiority trial

  2023cites this paper
• Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics

  2023cites this paper
• Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults

  2023cites this paper
• Two-phase modeling of fluid injection inside subcutaneous layer of skin

  2022cites this paper
• Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins

  2022cites this paper
• Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

  2022cites this paper
• Advancing Biologic Therapy for Refractory Autoimmune Hepatitis

  2022cites this paper
• Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

  2022cites this paper
• Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study

  2022cites this paper
• Evaluation of in vitro tools to predict the in vivo absorption of biopharmaceuticals following subcutaneous administration.

  2022cites this paper
• Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study

  2022cites this paper
• Viscosity reduction and stability enhancement of monoclonal antibody formulations using derivatives of amino acids.

  2022cites this paper
• Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit

  2022cites this paper
• Formulation and device lifecycle management of biotherapeutics—leveraging synergies across therapeutic areas

  2022cites this paper
• Editorial: intravenous to subcutaneous vedolizumab—switch without glitch!

  2022cites this paper
• The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting.

  2022cites this paper
• Enabling faster subcutaneous delivery of larger volume, high viscosity fluids

  2022cites this paper
• Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

  2022cites this paper
• Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

  2022cites this paper
• Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

  2022cites this paper
• Subcutaneously administered antibiotics: a review.

  2022cites this paper
• Random Heteropolymer Excipients Improve the Colloidal Stability of a Monoclonal Antibody for Subcutaneous Administration

  2022cites this paper
• Understanding patient preferences for handheld autoinjectors versus wearable large-volume injectors

  2022cites this paper
• Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies—pharmacokinetic-based bridging approach

  2022cites this paper
• Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma

  2022cites this paper
• PPA_A_303279 811..834

  2021cites this paper
• Subcutaneous drug delivery devices—Enablers of a flexible care setting

  2021cites this paper
• Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans

  2021cites this paper
• Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements

  2021cites this paper
• The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Goes Home.

  2021cites this paper
• Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review

  2021cites this paper
• Subcutaneous Injection Site Pain of Formulation Matrices

  2021cites this paper
• Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B

  2021cites this paper
• Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample

  2021cites this paper